

# Keith A Johnson

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5227545/publications.pdf>

Version: 2024-02-01

370  
papers

23,443  
citations

12303

69  
h-index

9311

143  
g-index

441  
all docs

441  
docs citations

441  
times ranked

19271  
citing authors

#	ARTICLE	IF	CITATIONS
1	Cortical Hubs Revealed by Intrinsic Functional Connectivity: Mapping, Assessment of Stability, and Relation to Alzheimer's Disease. <i>Journal of Neuroscience</i> , 2009, 29, 1860-1873.	1.7	2,576
2	A/T/N: An unbiased descriptive classification scheme for Alzheimer disease biomarkers. <i>Neurology</i> , 2016, 87, 539-547.	1.5	1,216
3	Amyloid Deposition Is Associated with Impaired Default Network Function in Older Persons without Dementia. <i>Neuron</i> , 2009, 63, 178-188.	3.8	899
4	Tau positron emission tomographic imaging in aging and early Alzheimer disease. <i>Annals of Neurology</i> , 2016, 79, 110-119.	2.8	778
5	The Centiloid Project: Standardizing quantitative amyloid plaque estimation by PET. <i>Alzheimer's and Dementia</i> , 2015, 11, 1.	0.4	603
6	The A4 Study: Stopping AD Before Symptoms Begin?. <i>Science Translational Medicine</i> , 2014, 6, 228fs13.	5.8	588
7	The Evolution of Preclinical Alzheimer's Disease: Implications for Prevention Trials. <i>Neuron</i> , 2014, 84, 608-622.	3.8	568
8	Validating novel tau positron emission tomography tracer [ <sup>18</sup> F]AV-451 (T807) on postmortem brain tissue. <i>Annals of Neurology</i> , 2015, 78, 787-800.	2.8	535
9	Disruption of Functional Connectivity in Clinically Normal Older Adults Harboring Amyloid Burden. <i>Journal of Neuroscience</i> , 2009, 29, 12686-12694.	1.7	530
10	Association of Amyloid and Tau With Cognition in Preclinical Alzheimer Disease. <i>JAMA Neurology</i> , 2019, 76, 915.	4.5	512
11	Brain Imaging in Alzheimer Disease. <i>Cold Spring Harbor Perspectives in Medicine</i> , 2012, 2, a006213-a006213.	2.9	502
12	Functional Alterations in Memory Networks in Early Alzheimer's Disease. <i>NeuroMolecular Medicine</i> , 2010, 12, 27-43.	1.8	497
13	Imaging of amyloid burden and distribution in cerebral amyloid angiopathy. <i>Annals of Neurology</i> , 2007, 62, 229-234.	2.8	465
14	Appropriate use criteria for amyloid PET: A report of the Amyloid Imaging Task Force, the Society of Nuclear Medicine and Molecular Imaging, and the Alzheimer's Association. <i>Alzheimer's and Dementia</i> , 2013, 9, e-1-16.	0.4	443
15	Subjective cognitive complaints and amyloid burden in cognitively normal older individuals. <i>Neuropsychologia</i> , 2012, 50, 2880-2886.	0.7	379
16	Resistance to autosomal dominant Alzheimer's disease in an APOE3 Christchurch homozygote: a case report. <i>Nature Medicine</i> , 2019, 25, 1680-1683.	15.2	328
17	Amyloid $\beta$ associated cortical thinning in clinically normal elderly. <i>Annals of Neurology</i> , 2011, 69, 1032-1042.	2.8	306
18	Synergistic Effect of $\beta$ -Amyloid and Neurodegeneration on Cognitive Decline in Clinically Normal Individuals. <i>JAMA Neurology</i> , 2014, 71, 1379.	4.5	273

#	ARTICLE	IF	CITATIONS
19	Appropriate Use Criteria for Amyloid PET: A Report of the Amyloid Imaging Task Force, the Society of Nuclear Medicine and Molecular Imaging, and the Alzheimer's Association. <i>Journal of Nuclear Medicine</i> , 2013, 54, 476-490.	2.8	248
20	Amyloid and APOE $\epsilon 4$ interact to influence short-term decline in preclinical Alzheimer disease. <i>Neurology</i> , 2014, 82, 1760-1767.	1.5	246
21	Phases of Hyperconnectivity and Hypoconnectivity in the Default Mode and Salience Networks Track with Amyloid and Tau in Clinically Normal Individuals. <i>Journal of Neuroscience</i> , 2017, 37, 4323-4331.	1.7	237
22	Association of In Vivo $^{18}F$ AV-1451 Tau PET Imaging Results With Cortical Atrophy and Symptoms in Typical and Atypical Alzheimer Disease. <i>JAMA Neurology</i> , 2017, 74, 427.	4.5	236
23	Different partial volume correction methods lead to different conclusions: An $^{18}F$ -FDG-PET study of aging. <i>NeuroImage</i> , 2016, 132, 334-343.	2.1	216
24	Amyloid- $\beta$ deposition in mild cognitive impairment is associated with increased hippocampal activity, atrophy and clinical progression. <i>Brain</i> , 2015, 138, 1023-1035.	3.7	207
25	Sex Differences in the Association of Global Amyloid and Regional Tau Deposition Measured by Positron Emission Tomography in Clinically Normal Older Adults. <i>JAMA Neurology</i> , 2019, 76, 542.	4.5	201
26	Florbetapir ( $^{18}F$ -AV-45) PET to assess amyloid burden in Alzheimer's disease dementia, mild cognitive impairment, and normal aging. <i>Alzheimer's and Dementia</i> , 2013, 9, S72-83.	0.4	200
27	Structural tract alterations predict downstream tau accumulation in amyloid-positive older individuals. <i>Nature Neuroscience</i> , 2018, 21, 424-431.	7.1	198
28	Partial volume correction in quantitative amyloid imaging. <i>NeuroImage</i> , 2015, 107, 55-64.	2.1	188
29	Association of Factors With Elevated Amyloid Burden in Clinically Normal Older Individuals. <i>JAMA Neurology</i> , 2020, 77, 735.	4.5	182
30	Longitudinal Association of Amyloid Beta and Anxious-Depressive Symptoms in Cognitively Normal Older Adults. <i>American Journal of Psychiatry</i> , 2018, 175, 530-537.	4.0	175
31	Impaired default network functional connectivity in autosomal dominant Alzheimer disease. <i>Neurology</i> , 2013, 81, 736-744.	1.5	174
32	Pathological correlations of $^{18}F$ -AV-1451 imaging in non-Alzheimer tauopathies. <i>Annals of Neurology</i> , 2017, 81, 117-128.	2.8	174
33	The impact of amyloid- $\beta$ and tau on prospective cognitive decline in older individuals. <i>Annals of Neurology</i> , 2019, 85, 181-193.	2.8	171
34	Subjective Cognitive Concerns and Neuropsychiatric Predictors of Progression to the Early Clinical Stages of Alzheimer Disease. <i>American Journal of Geriatric Psychiatry</i> , 2014, 22, 1642-1651.	0.6	167
35	Interactive Associations of Vascular Risk and $\beta$ -Amyloid Burden With Cognitive Decline in Clinically Normal Elderly Individuals. <i>JAMA Neurology</i> , 2018, 75, 1124.	4.5	165
36	Association of Higher Cortical Amyloid Burden With Loneliness in Cognitively Normal Older Adults. <i>JAMA Psychiatry</i> , 2016, 73, 1230.	6.0	164

#	ARTICLE	IF	CITATIONS
37	In Vivo Tau, Amyloid, and Gray Matter Profiles in the Aging Brain. <i>Journal of Neuroscience</i> , 2016, 36, 7364-7374.	1.7	153
38	<sup>18</sup> F-flortaucipir tau positron emission tomography distinguishes established progressive supranuclear palsy from controls and Parkinson disease: A multicenter study. <i>Annals of Neurology</i> , 2017, 82, 622-634.	2.8	148
39	Multiple Brain Markers are Linked to Age-Related Variation in Cognition. <i>Cerebral Cortex</i> , 2016, 26, 1388-1400.	1.6	146
40	Structural network alterations and neurological dysfunction in cerebral amyloid angiopathy. <i>Brain</i> , 2015, 138, 179-188.	3.7	145
41	Early and late change on the preclinical Alzheimer's cognitive composite in clinically normal older individuals with elevated amyloid $\beta$ . <i>Alzheimer's and Dementia</i> , 2017, 13, 1004-1012.	0.4	139
42	Association Between Amyloid and Tau Accumulation in Young Adults With Autosomal Dominant Alzheimer Disease. <i>JAMA Neurology</i> , 2018, 75, 548.	4.5	137
43	Neurogenetic contributions to amyloid beta and tau spreading in the human cortex. <i>Nature Medicine</i> , 2018, 24, 1910-1918.	15.2	135
44	CD33 modulates TREM2: convergence of Alzheimer loci. <i>Nature Neuroscience</i> , 2015, 18, 1556-1558.	7.1	134
45	Subjective cognitive concerns, amyloid- $\beta$ , and neurodegeneration in clinically normal elderly. <i>Neurology</i> , 2015, 85, 56-62.	1.5	127
46	Odor identification and Alzheimer disease biomarkers in clinically normal elderly. <i>Neurology</i> , 2015, 84, 2153-2160.	1.5	120
47	Region-Specific Association of Subjective Cognitive Decline With Tauopathy Independent of Global $\beta$ -Amyloid Burden. <i>JAMA Neurology</i> , 2017, 74, 1455.	4.5	119
48	The cortical origin and initial spread of medial temporal tauopathy in Alzheimer's disease assessed with positron emission tomography. <i>Science Translational Medicine</i> , 2021, 13, .	5.8	111
49	Fluorodeoxyglucose metabolism associated with tau-amyloid interaction predicts memory decline. <i>Annals of Neurology</i> , 2017, 81, 583-596.	2.8	110
50	Harvard Aging Brain Study: Dataset and accessibility. <i>NeuroImage</i> , 2017, 144, 255-258.	2.1	107
51	In vivo and neuropathology data support locus coeruleus integrity as indicator of Alzheimer's disease pathology and cognitive decline. <i>Science Translational Medicine</i> , 2021, 13, eabj2511.	5.8	107
52	Development of a process to disclose amyloid imaging results to cognitively normal older adult research participants. <i>Alzheimer's Research and Therapy</i> , 2015, 7, 26.	3.0	106
53	Functional network integrity presages cognitive decline in preclinical Alzheimer disease. <i>Neurology</i> , 2017, 89, 29-37.	1.5	106
54	Autoradiography validation of novel tau PET tracer [F-18]-MK-6240 on human postmortem brain tissue. <i>Acta Neuropathologica Communications</i> , 2019, 7, 37.	2.4	105

#	ARTICLE	IF	CITATIONS
55	Associations of Physical Activity and $\beta$ -Amyloid With Longitudinal Cognition and Neurodegeneration in Clinically Normal Older Adults. <i>JAMA Neurology</i> , 2019, 76, 1203.	4.5	97
56	Prevalence Estimates of Amyloid Abnormality Across the Alzheimer Disease Clinical Spectrum. <i>JAMA Neurology</i> , 2022, 79, 228.	4.5	97
57	Cortical atrophy in patients with cerebral amyloid angiopathy: a case-control study. <i>Lancet Neurology</i> , The, 2016, 15, 811-819.	4.9	96
58	PET staging of amyloidosis using striatum. <i>Alzheimer's and Dementia</i> , 2018, 14, 1281-1292.	0.4	93
59	Update on appropriate use criteria for amyloid PET imaging: Dementia experts, mild cognitive impairment, and education. <i>Alzheimer's and Dementia</i> , 2013, 9, e106-9.	0.4	90
60	Tau and amyloid $\beta$ proteins distinctively associate to functional network changes in the aging brain. <i>Alzheimer's and Dementia</i> , 2017, 13, 1261-1269.	0.4	90
61	Depressive Symptoms and Biomarkers of Alzheimer's Disease in Cognitively Normal Older Adults. <i>Journal of Alzheimer's Disease</i> , 2015, 46, 63-73.	1.2	87
62	Regional Cortical Thinning Predicts Worsening Apathy and Hallucinations Across the Alzheimer Disease Spectrum. <i>American Journal of Geriatric Psychiatry</i> , 2014, 22, 1168-1179.	0.6	86
63	Temporal T807 binding correlates with CSF tau and phospho-tau in normal elderly. <i>Neurology</i> , 2016, 87, 920-926.	1.5	86
64	Lessons learned about [F-18]-AV-1451 off-target binding from an autopsy-confirmed Parkinson's case. <i>Acta Neuropathologica Communications</i> , 2017, 5, 75.	2.4	85
65	Alzheimer's Disease Biomarkers and Future Decline in Cognitive Normal Older Adults. <i>Journal of Alzheimer's Disease</i> , 2017, 60, 1451-1459.	1.2	80
66	Flortaucipir tau PET imaging in semantic variant primary progressive aphasia. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2018, 89, 1024-1031.	0.9	80
67	Florbetapir-PET to diagnose cerebral amyloid angiopathy. <i>Neurology</i> , 2016, 87, 2043-2049.	1.5	79
68	Preferential degradation of cognitive networks differentiates Alzheimer's disease from ageing. <i>Brain</i> , 2018, 141, 1486-1500.	3.7	79
69	Vascular Risk and $\beta$ -Amyloid Are Synergistically Associated with Cortical Tau. <i>Annals of Neurology</i> , 2019, 85, 272-279.	2.8	75
70	Tau Accumulation in Clinically Normal Older Adults Is Associated with Hippocampal Hyperactivity. <i>Journal of Neuroscience</i> , 2019, 39, 548-556.	1.7	75
71	The association between tau PET and retrospective cortical thinning in clinically normal elderly. <i>NeuroImage</i> , 2017, 157, 612-622.	2.1	74
72	Pharmacokinetic Evaluation of the Tau PET Radiotracer $^{18}\text{F}$ -T807 ( $^{18}\text{F}$ -AV-1451) in Human Subjects. <i>Journal of Nuclear Medicine</i> , 2017, 58, 484-491.	2.8	73

#	ARTICLE	IF	CITATIONS
73	Longitudinal Association of Depression Symptoms With Cognition and Cortical Amyloid Among Community-Dwelling Older Adults. <i>JAMA Network Open</i> , 2019, 2, e198964.	2.8	72
74	A concise radiosynthesis of the tau radiopharmaceutical, [ <sup>18</sup> F]T807. <i>Journal of Labelled Compounds and Radiopharmaceuticals</i> , 2013, 56, 736-740.	0.5	70
75	Depressive Symptoms and Tau Accumulation in the Inferior Temporal Lobe and Entorhinal Cortex in Cognitively Normal Older Adults: A Pilot Study. <i>Journal of Alzheimer's Disease</i> , 2017, 59, 975-985.	1.2	70
76	In vivo rate-determining steps of tau seed accumulation in Alzheimer's disease. <i>Science Advances</i> , 2021, 7, eabh1448.	4.7	70
77	Memory self-awareness in the preclinical and prodromal stages of Alzheimer's disease. <i>Neuropsychologia</i> , 2017, 99, 343-349.	0.7	67
78	<sup>18</sup> F-Flortaucipir Binding in Choroid Plexus: Related to Race and Hippocampus Signal. <i>Journal of Alzheimer's Disease</i> , 2018, 62, 1691-1702.	1.2	67
79	Amyloid Deposition Is Linked to Aberrant Entorhinal Activity among Cognitively Normal Older Adults. <i>Journal of Neuroscience</i> , 2014, 34, 5200-5210.	1.7	65
80	The Apathy Evaluation Scale: A Comparison of Subject, Informant, and Clinician Report in Cognitively Normal Elderly and Mild Cognitive Impairment. <i>Journal of Alzheimer's Disease</i> , 2015, 47, 421-432.	1.2	65
81	Sex Mediates Relationships Between Regional Tau Pathology and Cognitive Decline. <i>Annals of Neurology</i> , 2020, 88, 921-932.	2.8	63
82	Update on Appropriate Use Criteria for Amyloid PET Imaging: Dementia Experts, Mild Cognitive Impairment, and Education. <i>Journal of Nuclear Medicine</i> , 2013, 54, 1011-1013.	2.8	61
83	Anosognosia for memory deficits in mild cognitive impairment: Insight into the neural mechanism using functional and molecular imaging. <i>NeuroImage: Clinical</i> , 2017, 15, 408-414.	1.4	61
84	Hierarchical Organization of Tau and Amyloid Deposits in the Cerebral Cortex. <i>JAMA Neurology</i> , 2017, 74, 813.	4.5	61
85	Biomarker validation of a decline in semantic processing in preclinical Alzheimer's disease. <i>Neuropsychologia</i> , 2016, 30, 624-630.	1.0	60
86	Free and cued memory in relation to biomarker-defined abnormalities in clinically normal older adults and those at risk for Alzheimer's disease. <i>Neuropsychologia</i> , 2015, 73, 169-175.	0.7	57
87	Accelerated decline in white matter integrity in clinically normal individuals at risk for Alzheimer's disease. <i>Neurobiology of Aging</i> , 2016, 42, 177-188.	1.5	57
88	Social Engagement and Amyloid- $\beta$ -Related Cognitive Decline in Cognitively Normal Older Adults. <i>American Journal of Geriatric Psychiatry</i> , 2019, 27, 1247-1256.	0.6	56
89	Graph Convolutional Neural Networks For Alzheimer's Disease Classification. , 2019, 2019, 414-417.		55
90	Clinical meaningfulness of subtle cognitive decline on longitudinal testing in preclinical AD. <i>Alzheimer's and Dementia</i> , 2020, 16, 552-560.	0.4	55

#	ARTICLE	IF	CITATIONS
91	Cognitive resilience in clinical and preclinical Alzheimer's disease: the Association of Amyloid and Tau Burden on cognitive performance. <i>Brain Imaging and Behavior</i> , 2017, 11, 383-390.	1.1	54
92	Associations between baseline amyloid, sex, and APOE on subsequent tau accumulation in cerebrospinal fluid. <i>Neurobiology of Aging</i> , 2019, 78, 178-185.	1.5	54
93	Estimating Total Cerebral Microinfarct Burden From Diffusion-Weighted Imaging. <i>Stroke</i> , 2015, 46, 2129-2135.	1.0	52
94	Heterogeneity in Suspected Non-Alzheimer Disease Pathophysiology Among Clinically Normal Older Individuals. <i>JAMA Neurology</i> , 2016, 73, 1185.	4.5	52
95	Regional Cortical Thinning and Cerebrospinal Biomarkers Predict Worsening Daily Functioning Across the Alzheimer's Disease Spectrum. <i>Journal of Alzheimer's Disease</i> , 2014, 41, 719-728.	1.2	51
96	Amyloid-associated increases in longitudinal report of subjective cognitive complaints. <i>Alzheimer's and Dementia: Translational Research and Clinical Interventions</i> , 2018, 4, 444-449.	1.8	51
97	White matter hyperintensities and the mediating role of cerebral amyloid angiopathy in dominantly-inherited Alzheimer's disease. <i>PLoS ONE</i> , 2018, 13, e0195838.	1.1	51
98	Hippocampal hypometabolism in older adults with memory complaints and increased amyloid burden. <i>Neurology</i> , 2017, 88, 1759-1767.	1.5	50
99	Dedifferentiation of caudate functional connectivity and striatal dopamine transporter density predict memory change in normal aging. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2018, 115, 10160-10165.	3.3	49
100	Short-term Psychological Outcomes of Disclosing Amyloid Imaging Results to Research Participants Who Do Not Have Cognitive Impairment. <i>JAMA Neurology</i> , 2020, 77, 1504.	4.5	48
101	Global White Matter Diffusion Characteristics Predict Longitudinal Cognitive Change Independently of Amyloid Status in Clinically Normal Older Adults. <i>Cerebral Cortex</i> , 2019, 29, 1251-1262.	1.6	47
102	Cued memory decline in biomarker-defined preclinical Alzheimer disease. <i>Neurology</i> , 2017, 88, 1431-1438.	1.5	46
103	Regional tau pathology and loneliness in cognitively normal older adults. <i>Translational Psychiatry</i> , 2018, 8, 282.	2.4	46
104	Quantitative Amyloid Imaging in Autosomal Dominant Alzheimer's Disease: Results from the DIAN Study Group. <i>PLoS ONE</i> , 2016, 11, e0152082.	1.1	45
105	Defining the Lowest Threshold for Amyloid-PET to Predict Future Cognitive Decline and Amyloid Accumulation. <i>Neurology</i> , 2021, 96, e619-e631.	1.5	45
106	Neuropsychiatric Symptoms and Functional Connectivity in Mild Cognitive Impairment. <i>Journal of Alzheimer's Disease</i> , 2015, 46, 727-735.	1.2	44
107	Lower Late-Life Body-Mass Index is Associated with Higher Cortical Amyloid Burden in Clinically Normal Elderly. <i>Journal of Alzheimer's Disease</i> , 2016, 53, 1097-1105.	1.2	44
108	PET imaging of tau protein targets: a methodology perspective. <i>Brain Imaging and Behavior</i> , 2019, 13, 333-344.	1.1	43

#	ARTICLE	IF	CITATIONS
109	Plasma N-terminal tau fragment levels predict future cognitive decline and neurodegeneration in healthy elderly individuals. <i>Nature Communications</i> , 2020, 11, 6024.	5.8	43
110	Current directions in tau research: Highlights from Tau 2020. <i>Alzheimer's and Dementia</i> , 2022, 18, 988-1007.	0.4	42
111	The Ups and Downs of the Posteromedial Cortex: Age- and Amyloid-Related Functional Alterations of the Encoding/Retrieval Flip in Cognitively Normal Older Adults. <i>Cerebral Cortex</i> , 2013, 23, 1317-1328.	1.6	41
112	Association Between Common Variants in <i>RBF1</i> , an RNA-Binding Protein, and Brain Amyloidosis in Early and Preclinical Alzheimer Disease. <i>JAMA Neurology</i> , 2020, 77, 1288.	4.5	41
113	Plasma IL-12/IFN- $\beta$ axis predicts cognitive trajectories in cognitively unimpaired older adults. <i>Alzheimer's and Dementia</i> , 2022, 18, 645-653.	0.4	39
114	Regional Fluorodeoxyglucose Metabolism and Instrumental Activities of Daily Living across the Alzheimer's Disease Spectrum. <i>Journal of Alzheimer's Disease</i> , 2014, 42, 291-300.	1.2	38
115	Association of Digital Clock Drawing With PET Amyloid and Tau Pathology in Normal Older Adults. <i>Neurology</i> , 2021, 96, e1844-e1854.	1.5	38
116	Microfluidic continuous-flow radiosynthesis of [ <sup>18</sup> F]FPEB suitable for human PET imaging. <i>MedChemComm</i> , 2014, 5, 432-435.	3.5	37
117	Regional 18F-Fluorodeoxyglucose Hypometabolism is Associated with Higher Apathy Scores Over Time in Early Alzheimer Disease. <i>American Journal of Geriatric Psychiatry</i> , 2017, 25, 683-693.	0.6	37
118	Partial volume correction for PET quantification and its impact on brain network in Alzheimer's disease. <i>Scientific Reports</i> , 2017, 7, 13035.	1.6	37
119	Cognitive activity relates to cognitive performance but not to Alzheimer disease biomarkers. <i>Neurology</i> , 2015, 85, 48-55.	1.5	36
120	Episodic memory of odors stratifies Alzheimer biomarkers in normal elderly. <i>Annals of Neurology</i> , 2016, 80, 846-857.	2.8	36
121	A Spectral Graph Regression Model for Learning Brain Connectivity of Alzheimer's Disease. <i>PLoS ONE</i> , 2015, 10, e0128136.	1.1	35
122	Neuroimaging markers associated with maintenance of optimal memory performance in late-life. <i>Neuropsychologia</i> , 2017, 100, 164-170.	0.7	35
123	Matched signal detection on graphs: Theory and application to brain imaging data classification. <i>NeuroImage</i> , 2016, 125, 587-600.	2.1	34
124	Longitudinal amyloid and tau accumulation in autosomal dominant Alzheimer's disease: findings from the Colombia-Boston (COLBOS) biomarker study. <i>Alzheimer's Research and Therapy</i> , 2021, 13, 27.	3.0	34
125	Variant-dependent heterogeneity in amyloid $\beta^2$ burden in autosomal dominant Alzheimer's disease: cross-sectional and longitudinal analyses of an observational study. <i>Lancet Neurology</i> , 2022, 21, 140-152.	4.9	34
126	[18F]-AV-1451 binding profile in chronic traumatic encephalopathy: a postmortem case series. <i>Acta Neuropathologica Communications</i> , 2019, 7, 164.	2.4	33



#	ARTICLE	IF	CITATIONS
127	Regional Tau Correlates of Instrumental Activities of Daily Living and Apathy in Mild Cognitive Impairment and Alzheimer's Disease Dementia. <i>Journal of Alzheimer's Disease</i> , 2019, 67, 757-768.	1.2	32
128	Lower novelty-related locus coeruleus function is associated with A $\beta$ -related cognitive decline in clinically healthy individuals. <i>Nature Communications</i> , 2022, 13, 1571.	5.8	32
129	Distinct tau neuropathology and cellular profiles of an APOE3 Christchurch homozygote protected against autosomal dominant Alzheimer's dementia. <i>Acta Neuropathologica</i> , 2022, 144, 589-601.	3.9	32
130	<i>Trans</i> -pQTL study identifies immune crosstalk between Parkinson and Alzheimer loci. <i>Neurology: Genetics</i> , 2016, 2, e90.	0.9	31
131	Serum neurofilament light chain levels are associated with white matter integrity in autosomal dominant Alzheimer's disease. <i>Neurobiology of Disease</i> , 2020, 142, 104960.	2.1	31
132	Inferior temporal tau is associated with accelerated prospective cortical thinning in clinically normal older adults. <i>NeuroImage</i> , 2020, 220, 116991.	2.1	31
133	Identifying Sensitive Measures of Cognitive Decline at Different Clinical Stages of Alzheimer's Disease. <i>Journal of the International Neuropsychological Society</i> , 2021, 27, 426-438.	1.2	30
134	Striatal and extrastriatal dopamine transporter levels relate to cognition in Lewy body diseases: an 11C altoprane positron emission tomography study. <i>Alzheimer's Research and Therapy</i> , 2014, 6, 52.	3.0	29
135	Divergent Cortical Tau Positron Emission Tomography Patterns Among Patients With Preclinical Alzheimer Disease. <i>JAMA Neurology</i> , 2022, 79, 592.	4.5	29
136	Menopause Status Moderates Sex Differences in Tau Burden: A Framingham PET Study. <i>Annals of Neurology</i> , 2022, 92, 11-22.	2.8	29
137	Association of anxiety with subcortical amyloidosis in cognitively normal older adults. <i>Molecular Psychiatry</i> , 2020, 25, 2599-2607.	4.1	28
138	PET Image Deblurring and Super-Resolution With an MR-Based Joint Entropy Prior. <i>IEEE Transactions on Computational Imaging</i> , 2019, 5, 530-539.	2.6	27
139	Associations of Widowhood and A $\beta$ -Amyloid With Cognitive Decline in Cognitively Unimpaired Older Adults. <i>JAMA Network Open</i> , 2020, 3, e200121.	2.8	27
140	Amyloid-beta burden predicts prospective decline in body mass index in clinically normal adults. <i>Neurobiology of Aging</i> , 2020, 93, 124-130.	1.5	27
141	Evaluation of pharmacokinetic modeling strategies for in-vivo quantification of tau with the radiotracer [18F]MK6240 in human subjects. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2019, 46, 2099-2111.	3.3	26
142	Inferior and medial temporal tau and cortical amyloid are associated with daily functional impairment in Alzheimer's disease. <i>Alzheimer's Research and Therapy</i> , 2019, 11, 14.	3.0	26
143	Striatal amyloid is associated with tauopathy and memory decline in familial Alzheimer's disease. <i>Alzheimer's Research and Therapy</i> , 2019, 11, 17.	3.0	26
144	Amyloid-A $\beta$ and tau pathologies relate to distinctive brain dysconnectomics in preclinical autosomal-dominant Alzheimer's disease. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2022, 119, e2113641119.	3.3	26

#	ARTICLE	IF	CITATIONS
145	Dopamine transporter availability in clinically normal aging is associated with individual differences in white matter integrity. <i>Human Brain Mapping</i> , 2016, 37, 621-631.	1.9	24
146	Decreased hippocampal metabolism in high-amyloid mild cognitive impairment. <i>Alzheimer's and Dementia</i> , 2016, 12, 1288-1296.	0.4	23
147	Neuropathologic correlates of amyloid and dopamine transporter imaging in Lewy body disease. <i>Neurology</i> , 2019, 93, e476-e484.	1.5	23
148	Resting-state functional connectivity and amyloid burden influence longitudinal cortical thinning in the default mode network in preclinical Alzheimer's disease. <i>NeuroImage: Clinical</i> , 2020, 28, 102407.	1.4	23
149	Amyloid imaging of dutch-type hereditary cerebral amyloid angiopathy carriers. <i>Annals of Neurology</i> , 2019, 86, 616-625.	2.8	22
150	Visual short-term memory relates to tau and amyloid burdens in preclinical autosomal dominant Alzheimer's disease. <i>Alzheimer's Research and Therapy</i> , 2020, 12, 99.	3.0	22
151	Impact of 40-Hz Transcranial Alternating Current Stimulation on Cerebral Tau Burden in Patients with Alzheimer's Disease: A Case Series. <i>Journal of Alzheimer's Disease</i> , 2022, 85, 1667-1676.	1.2	22
152	Amyloid imaging of Alzheimer's disease using pittsburgh compound B. <i>Current Neurology and Neuroscience Reports</i> , 2006, 6, 496-503.	2.0	21
153	Multi-Modal Signatures of Tau Pathology, Neuronal Fiber Integrity, and Functional Connectivity in Traumatic Brain Injury. <i>Journal of Neurotrauma</i> , 2019, 36, 3233-3243.	1.7	21
154	Association of Emerging $\beta$ -Amyloid and Tau Pathology With Early Cognitive Changes in Clinically Normal Older Adults. <i>Neurology</i> , 2022, 98, .	1.5	20
155	Using subjective cognitive decline to identify high global amyloid in community-based samples: A cross-cohort study. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2019, 11, 670-678.	1.2	19
156	Monthly At-Home Computerized Cognitive Testing to Detect Diminished Practice Effects in Preclinical Alzheimer's Disease. <i>Frontiers in Aging Neuroscience</i> , 2021, 13, 800126.	1.7	19
157	Longitudinal degradation of the default/salience network axis in symptomatic individuals with elevated amyloid burden.. <i>NeuroImage: Clinical</i> , 2020, 26, 102052.	1.4	18
158	Examining Cognitive Decline Across Black and White Participants in the Harvard Aging Brain Study. <i>Journal of Alzheimer's Disease</i> , 2020, 75, 1437-1446.	1.2	18
159	Comparing PET and MRI Biomarkers Predicting Cognitive Decline in Preclinical Alzheimer Disease. <i>Neurology</i> , 2021, 96, .	1.5	18
160	Non-Alcoholic Fatty Liver Disease, Liver Fibrosis, and Regional Amyloid- $\beta$ and Tau Pathology in Middle-Aged Adults: The Framingham Study. <i>Journal of Alzheimer's Disease</i> , 2022, 86, 1371-1383.	1.2	18
161	Case 1-2017. <i>New England Journal of Medicine</i> , 2017, 376, 158-167.	13.9	17
162	The influence of demographic factors on subjective cognitive concerns and beta-amyloid. <i>International Psychogeriatrics</i> , 2017, 29, 645-652.	0.6	17

#	ARTICLE	IF	CITATIONS
163	Visual cognition in non-amnesic Alzheimer's disease: Relations to tau, amyloid, and cortical atrophy. <i>NeuroImage: Clinical</i> , 2019, 23, 101889.	1.4	17
164	Synergism between fornix microstructure and beta amyloid accelerates memory decline in clinically normal older adults. <i>Neurobiology of Aging</i> , 2019, 81, 38-46.	1.5	17
165	Word retrieval across the biomarker-confirmed Alzheimer's disease syndromic spectrum. <i>Neuropsychologia</i> , 2020, 140, 107391.	0.7	17
166	Association of cortical microstructure with amyloid- $\beta^2$ and tau: impact on cognitive decline, neurodegeneration, and clinical progression in older adults. <i>Molecular Psychiatry</i> , 2021, 26, 7813-7822.	4.1	17
167	Linear Regression with a Randomly Censored Covariate: Application to an Alzheimer's Study. <i>Journal of the Royal Statistical Society Series C: Applied Statistics</i> , 2017, 66, 313-328.	0.5	16
168	Nonlinear Distributional Mapping (NoDiM) for harmonization across amyloid-PET radiotracers. <i>NeuroImage</i> , 2019, 186, 446-454.	2.1	16
169	Association of Memory Impairment With Concomitant Tau Pathology in Patients With Cerebral Amyloid Angiopathy. <i>Neurology</i> , 2021, 96, e1975-e1986.	1.5	16
170	Topography of cortical thinning in the Lewy body diseases. <i>NeuroImage: Clinical</i> , 2020, 26, 102196.	1.4	15
171	Decline in cognitively complex everyday activities accelerates along the Alzheimer's disease continuum. <i>Alzheimer's Research and Therapy</i> , 2020, 12, 138.	3.0	14
172	Attenuation correction using deep Learning and integrated UTE/multi-echo Dixon sequence: evaluation in amyloid and tau PET imaging. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2021, 48, 1351-1361.	3.3	14
173	The Harvard Automated Phone Task: new performance-based activities of daily living tests for early Alzheimer's disease. <i>Journal of Prevention of Alzheimer's Disease</i> , 2015, 2, 242-253.	1.5	14
174	The presubiculum links incipient amyloid and tau pathology to memory function in older persons. <i>Neurology</i> , 2020, 94, e1916-e1928.	1.5	13
175	Anticholinergic Amnesia is Mediated by Alterations in Human Network Connectivity Architecture. <i>Cerebral Cortex</i> , 2019, 29, 3445-3456.	1.6	12
176	MR-based PET attenuation correction using a combined ultrashort echo time/multi-echo Dixon acquisition. <i>Medical Physics</i> , 2020, 47, 3064-3077.	1.6	12
177	Maternal dementia age at onset in relation to amyloid burden in non-demented elderly offspring. <i>Neurobiology of Aging</i> , 2016, 40, 61-67.	1.5	11
178	The relationship between recall of recently versus remotely encoded famous faces and amyloidosis in clinically normal older adults. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2018, 10, 121-129.	1.2	11
179	Impaired memory is more closely associated with brain beta-amyloid than leukoaraiosis in hypertensive patients with cognitive symptoms. <i>PLoS ONE</i> , 2018, 13, e0191345.	1.1	11
180	Waning locus coeruleus integrity precedes cortical tau accrual in preclinical autosomal dominant Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2023, 19, 169-180.	0.4	11

#	ARTICLE	IF	CITATIONS
181	Associations of Stages of Objective Memory Impairment With Amyloid PET and Structural MRI. <i>Neurology</i> , 2022, 98, .	1.5	10
182	Association of Aortic Stiffness and Pressure Pulsatility With Global Amyloid- $\beta^2$ and Regional Tau Burden Among Framingham Heart Study Participants Without Dementia. <i>JAMA Neurology</i> , 2022, 79, 710.	4.5	10
183	Threshold Regression to Accommodate a Censored Covariate. <i>Biometrics</i> , 2018, 74, 1261-1270.	0.8	9
184	Measuring instrumental activities of daily living in non-demented elderly: a comparison of the new performance-based Harvard Automated Phone Task with other functional assessments. <i>Alzheimer's Research and Therapy</i> , 2019, 11, 4.	3.0	9
185	The neurophysiology and seizure outcomes of late onset unexplained epilepsy. <i>Clinical Neurophysiology</i> , 2020, 131, 2667-2672.	0.7	9
186	Association of Midlife Depressive Symptoms with Regional Amyloid- $\beta^2$ and Tau in the Framingham Heart Study. <i>Journal of Alzheimer's Disease</i> , 2021, 82, 249-260.	1.2	9
187	Effect of vascular amyloid on white matter disease is mediated by vascular dysfunction in cerebral amyloid angiopathy. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2022, 42, 1272-1281.	2.4	9
188	Imaging Dementia with SPECT. <i>Annals of the New York Academy of Sciences</i> , 1991, 620, 165-174.	1.8	8
189	Functional Connectivity in Alzheimer's Disease: Measurement and Meaning. <i>Biological Psychiatry</i> , 2013, 74, 318-319.	0.7	8
190	Interactive versus additive relationships between regional cortical thinning and amyloid burden in predicting clinical decline in mild AD and MCI individuals. <i>NeuroImage: Clinical</i> , 2018, 17, 388-396.	1.4	8
191	Multiple markers contribute to risk of progression from normal to mild cognitive impairment. <i>NeuroImage: Clinical</i> , 2020, 28, 102400.	1.4	8
192	Associations between plasma neurofilament light, in vivo brain pathology, and cognition in non-demented individuals with autosomal-dominant Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2021, 17, 813-821.	0.4	8
193	Longitudinal predictive modeling of tau progression along the structural connectome. <i>NeuroImage</i> , 2021, 237, 118126.	2.1	8
194	Activities of daily living measured by the Harvard Automated Phone Task track with cognitive decline over time in non-demented elderly. <i>Journal of Prevention of Alzheimer's Disease, The</i> , 2017, 4, 81-86.	1.5	8
195	Blood Phosphorylated Tau 181 as a Biomarker for Amyloid Burden on Brain PET in Cognitively Healthy Adults. <i>Journal of Alzheimer's Disease</i> , 2022, 87, 1517-1526.	1.2	8
196	Association of $\beta^2$ -Amyloid and Vascular Risk on Longitudinal Patterns of Brain Atrophy. <i>Neurology</i> , 2022, 99, .	1.5	8
197	Decreased meta-memory is associated with early tauopathy in cognitively unimpaired older adults. <i>NeuroImage: Clinical</i> , 2019, 24, 102097.	1.4	7
198	Functional and Pathological Correlates of Judgments of Learning in Cognitively Unimpaired Older Adults. <i>Cerebral Cortex</i> , 2020, 30, 1974-1983.	1.6	7

#	ARTICLE	IF	CITATIONS
199	Association of subjective cognitive decline with markers of brain pathology in preclinical autosomal dominant Alzheimer's disease. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2020, 91, 330-332.	0.9	7
200	The Latin American Spanish version of the Face-Name Associative Memory Exam is sensitive to cognitive and pathological changes in preclinical autosomal dominant Alzheimer's disease. <i>Alzheimer's Research and Therapy</i> , 2020, 12, 104.	3.0	7
201	Associative memory and in vivo brain pathology in asymptomatic presenilin-1 E280A carriers. <i>Neurology</i> , 2020, 95, e1312-e1321.	1.5	7
202	<sup>18</sup> F-AV-1451 positron emission tomography in neuropathological substrates of corticobasal syndrome. <i>Brain</i> , 2021, 144, 266-277.	3.7	7
203	Longitudinal Trajectories of Participant- and Study Partner-Rated Cognitive Decline, in Relation to Alzheimer's Disease Biomarkers and Mood Symptoms. <i>Frontiers in Aging Neuroscience</i> , 2021, 13, 806432.	1.7	7
204	Heterogeneity of Tau Deposition and Microvascular Involvement in MCI and AD. <i>Current Alzheimer Research</i> , 2021, 18, 711-720.	0.7	6
205	Multiple imputation of a randomly censored covariate improves logistic regression analysis. <i>Journal of Applied Statistics</i> , 2016, 43, 2886-2896.	0.6	5
206	An UNC5C Allele Predicts Cognitive Decline and Hippocampal Atrophy in Clinically Normal Older Adults. <i>Journal of Alzheimer's Disease</i> , 2019, 68, 1161-1170.	1.2	5
207	Epicenters of dynamic connectivity in the adaptation of the ventral visual system. <i>Human Brain Mapping</i> , 2017, 38, 1965-1976.	1.9	4
208	O1-02-01: IMAGING TAU PATHOLOGY <i>IN VIVO</i> IN FTLD: INITIAL EXPERIENCE WITH [ <sup>18</sup> F] T807 PET. <i>Alzheimer's and Dementia</i> , 2014, 10, P131.	0.4	3
209	IC-P-213: IMAGING TAU PATHOLOGY <i>IN VIVO</i> IN FTLD: INITIAL EXPERIENCE WITH [ <sup>18</sup> F] T807 PET. , 2014, 10, P115-P115.		3
210	F2-02-03: TAU AND AB DEPOSITS RELATE TO DISTINCTIVE FUNCTIONAL CONNECTIVITY DISRUPTIONS IN THE ELDERLY BRAIN. , 2014, 10, P159-P160.		3
211	O1-02-02: THE ANTI-AMYLOID TREATMENT IN ASYMPTOMATIC ALZHEIMER'S DISEASE (A4) STUDY: REPORT OF SCREENING DATA RESULTS. <i>Alzheimer's and Dementia</i> , 2018, 14, P215.	0.4	3
212	Alzheimer's disease biomarker roadmap 2020: Time for tau. <i>Alzheimer's and Dementia</i> , 2020, 16, e039549.	0.4	3
213	IC-P-162: Entorhinal, parahippocampal, and inferior temporal F18-T807 SUVR correlates with CSF total tau and tau T181P in cognitively normal elderly. , 2015, 11, P109-P109.		2
214	[ <sup>18</sup> F]-PA-181: LONGITUDINAL TAU ACCUMULATION IS ASSOCIATED WITH COGNITIVE DECLINE IN NORMAL ELDERLY. <i>Alzheimer's and Dementia</i> , 2017, 13, P134.	0.4	2
215	Grip strength and gait speed as early biomarkers of brain amyloid and tau deposition. <i>Alzheimer's and Dementia</i> , 2020, 16, e041178.	0.4	2
216	Hypoconnectivity between locus coeruleus and medial temporal lobe during novelty predicts accelerated A $\beta$ -related cognitive decline. <i>Alzheimer's and Dementia</i> , 2020, 16, e041323.	0.4	2

#	ARTICLE	IF	CITATIONS
217	Blood phosphorylated tau 181 predicts early, preclinical brain amyloid deposition. <i>Alzheimer's and Dementia</i> , 2021, 17, .	0.4	2
218	Amyloid $\beta$ and tau pathologies relate to distinctive brain dysconnectomics in autosomal $\beta$ -dominant Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2021, 17, .	0.4	2
219	Preclinical Prediction of AD: Relation Between Neuropsychological and Neuroimaging Findings. , 0, , 97-110.		1
220	O2 $\beta$ : Disrupted functional connectivity in autosomal dominant Alzheimer's disease: Preliminary findings from the DIAN study. <i>Alzheimer's and Dementia</i> , 2012, 8, P244.	0.4	1
221	P1-180: A NEW PERFORMANCE-BASED ACTIVITIES OF DAILY LIVING INSTRUMENT FOR EARLY ALZHEIMER'S DISEASE. , 2014, 10, P365-P365.		1
222	IC-P-087: DETECTING COGNITIVE PROFILES IN THE BIOMARKER STAGES OF PRECLINICAL AD. , 2014, 10, P49-P50.		1
223	P2-246: GREATER SUBJECTIVE COGNITIVE CONCERNS CORRESPOND WITH ADVANCING STAGES OF PRECLINICAL AD. , 2014, 10, P566-P566.		1
224	P4-064: Longitudinal 18 F-T807 PET imaging in a case of nonfluent variant primary progressive aphasia. , 2015, 11, P791-P792.		1
225	O4-01-01: Regional Tau PET measures associated with memory performance in clinically normal older individuals. , 2015, 11, P265-P265.		1
226	F3-03-03: Disclosure of amyloid status in the a4 trial. , 2015, 11, P215-P215.		1
227	IC-P-068: The relationship of cognition, cognitive reserve, and in vivo tau and amyloid burden. , 2015, 11, P51-P51.		1
228	O4-01-04: Entorhinal, parahippocampal, and inferior temporal F18-T807 SUVR correlates with CSF total tau and tau T181P in cognitively normal elderly. , 2015, 11, P267-P267.		1
229	F5-05-02: The Harvard Automated Phone Task (APT): A Novel Performance-Based ADL Instrument for Early Alzheimer's Disease. , 2016, 12, P373-P373.		1
230	IC $\beta$ -013: Pet Staging of Amyloidosis: Evidence that Amyloid Occurs First in Neocortex and Later in Striatum. <i>Alzheimer's and Dementia</i> , 2016, 12, P20.	0.4	1
231	IC-P-043: Neuroimaging Correlates of Anosognosia in Mild Cognitive Impairment. , 2016, 12, P36-P37.		1
232	[P3 $\beta$ -376]: QRISK2 AND FRAMINGHAM CARDIOVASCULAR RISK SCORES SIGNIFICANTLY CORRELATE WITH IMAGING BIOMARKERS OF PRECLINICAL AD: FINDINGS FROM THE HARVARD AGING BRAIN STUDY. <i>Alzheimer's and Dementia</i> , 2017, 13, P1103.	0.4	1
233	[IC $\beta$ -02 $\beta$ -03]: TAU AND HIPPOCAMPAL VOLUME REFLECT DISTINCT PROCESSES IN PRECLINICAL ALZHEIMER'S DISEASE. <i>Alzheimer's and Dementia</i> , 2017, 13, P5.	0.4	1
234	[O1 $\beta$ -02 $\beta$ -05]: GENOTYPIC VARIANCE MAY EXPLAIN THE BALANCE OF EARLY CORTICAL VERSUS STRIATAL AMYLOID DEPOSITION IN AUTOSOMAL DOMINANT AD. <i>Alzheimer's and Dementia</i> , 2017, 13, P187.	0.4	1

#	ARTICLE	IF	CITATIONS
235	[P4â€“500]: SPATIAL PATTERNS OF FLORTAUCIPIR (FTP) SIGNAL IN COGNITIVELY NORMAL ELDERLY. Alzheimer's and Dementia, 2017, 13, P1530.	0.4	1
236	ICâ€Pâ€041: LONGITUDINAL CHANGE OF FUNCTIONAL CONNECTIVITY IN PRECLINICAL AD: RESULTS FROM THE HARVARD AGING BRAIN STUDY. Alzheimer's and Dementia, 2018, 14, P41.	0.4	1
237	O1â€08â€03: DIGITIZED CLOCK DRAWING (DCTCLOCK<sup>TM</sup>) PERFORMANCE AND ITS RELATIONSHIP TO AMYLOID AND TAU PET IMAGING MARKERS IN UNIMPAIRED OLDER ADULTS. Alzheimer's and Dementia, 2018, 14, P236.	0.4	1
238	P1â€480: LOCUS COERULEUS SIGNAL INTENSITY IS ASSOCIATED WITH ENTORHINAL TAU PATHOLOGY AT HIGHER LEVELS OF AMYLOID BURDEN. Alzheimer's and Dementia, 2018, 14, P509.	0.4	1
239	ICâ€02â€04: REGIONAL ASYMMETRIES IN AMYLOID AND TAU GO TOGETHER: EVIDENCE FOR LOCAL INTERACTION. Alzheimer's and Dementia, 2018, 14, P4.	0.4	1
240	ICâ€Pâ€147: QUANTIFYING STAGES OF SUBTLE MEMORY IMPAIRMENT IN PRECLINICAL ALZHEIMER'S DISEASE. Alzheimer's and Dementia, 2018, 14, P125.	0.4	1
241	Alzheimerâ€™s disease biomarker roadmap 2020: Secondâ€generation tau PET tracers. Alzheimer's and Dementia, 2020, 16, e039556.	0.4	1
242	AHEAD 3â€45 study: Preliminary screening and baseline characteristics from a placeboâ€controlled, doubleâ€blind study evaluating lecanemab in participants with preclinical Alzheimerâ€™s disease and elevated (A45 trial) and intermediate (A3 trial) amyloid. Alzheimer's and Dementia, 2021, 17, .	0.4	1
243	Extraneous neuroimaging factors do not contribute to sex differences in flortaucipir signal: Analysis of skull binding and partial volume effects. Alzheimer's and Dementia, 2021, 17, .	0.4	1
244	Associations between remote cognitive testing on an individualâ€™s own digital device and amyloid burden on neuroimaging in clinically normal older adults: Results from Boston Remote Assessment for Neurocognitive Health (BRANCH). Alzheimer's and Dementia, 2021, 17, .	0.4	1
245	O5-04-01: Pittsburgh compound B binding and MRI findings in nondemented hypertensive patients with cognitive concerns or mild cognitive impairment. , 2013, 9, P835-P835.		0
246	O4-06-03: Genotype-phenotype studies examining the CD33 locus and amyloid biology. , 2013, 9, P692-P693.		0
247	P3-266: NEUROPSYCHIATRIC SYMPTOMS AND FUNCTIONAL CONNECTIVITY IN MILD COGNITIVE IMPAIRMENT AND COGNITIVELY NORMAL ELDERLY. , 2014, 10, P729-P729.		0
248	IC-P-152: OLFATORY IDENTIFICATION AND ALZHEIMER'S DISEASE BIOMARKERS IN CLINICALLY NORMAL ELDERLY. , 2014, 10, P87-P87.		0
249	P1-301: OLFATORY IDENTIFICATION AND ALZHEIMER'S DISEASE BIOMARKERS IN CLINICALLY NORMAL ELDERLY. , 2014, 10, P422-P422.		0
250	O4-12-04: DETECTING COGNITIVE PROFILES IN THE BIOMARKER STAGES OF PRECLINICAL AD. , 2014, 10, P276-P276.		0
251	IC-P-084: Neurobiological correlates of anosognosia in mild cognitive impairment: A multimodal investigation using FDG-PET, PiB-PET, and volumetric MRI. , 2015, 11, P60-P60.		0
252	IC-P-125: Location, location, location: The distributed effects of amyloid on functional connectivity in the harvard aging brain study. , 2015, 11, P85-P86.		0

#	ARTICLE	IF	CITATIONS
253	P4-083: Hippocampal metabolism is decreased in high-amyloid mild cognitive impairment but not in high-amyloid clinically normal elders. , 2015, 11, P802-P803.		0
254	IC-P-071: Instrumental activities of daily living and functional connectivity in mild cognitive impairment. , 2015, 11, P53-P53.		0
255	IC-P-085: Regional Tau PET measures associated with memory performance in clinically normal older individuals. , 2015, 11, P60-P61.		0
256	IC-P-156: Baseline amyloid PET imaging, longitudinal amyloid accumulation, and Tau PET imaging in preclinical Alzheimer's disease. , 2015, 11, P105-P105.		0
257	P3-162: Instrumental activities of daily living and functional connectivity in mild cognitive impairment. , 2015, 11, P690-P691.		0
258	O4-01-03: Entorhinal tau deposition is associated with parietal association cortex hypometabolism in clinically normal older individuals. , 2015, 11, P266-P267.		0
259	F3-02-02: Snap in cognitively normal adults. , 2015, 11, P213-P213.		0
260	P2-141: Neurobiological correlates of anosognosia in mild cognitive impairment: A multi-modal investigation using FDG-PET, PiB-PET, and volumetric MRI. , 2015, 11, P540-P540.		0
261	O3-09-06: Location, location, location: The distributed effects of amyloid on functional connectivity in the harvard aging brain study. , 2015, 11, P240-P240.		0
262	O5-01-01: Tau and amyloid deposits relate to distinctive cortical atrophy patterns in cognitively normal elderly. , 2015, 11, P311-P312.		0
263	P3-135: Clinical and neuroimaging predictors of psychological well-being as measured by the purpose in life scale in cognitively normal older individuals. , 2015, 11, P675-P676.		0
264	IC-P-153: Clinical and neuroimaging predictors of psychological well-being as measured by the purpose in life scale in cognitively normal older individuals. , 2015, 11, P102-P103.		0
265	P2-151: Imaging tau pathology in vivo in ftdl with [18F] T807 PET. , 2015, 11, P545-P545.		0
266	O1-06-05: Baseline amyloid PET imaging, longitudinal amyloid accumulation, and Tau PET imaging in preclinical Alzheimer's disease. , 2015, 11, P139-P139.		0
267	O2-02-03: The relationship of cognition, cognitive reserve, and in vivo tau and amyloid burden. , 2015, 11, P175-P175.		0
268	O2-02-05: Differential declines in letter versus category fluency over 4 years in biomarker-defined preclinical Alzheimer's disease. , 2015, 11, P176-P177.		0
269	O4-01-05: The relationship between cortical atrophy and tau pathology measured in vivo with [18F] T807 PET. , 2015, 11, P267-P268.		0
270	P3-309: Profiles of Cognitive Decline Associated with Biomarker-Defined Preclinical Stages of Alzheimer's Disease. Alzheimer's and Dementia, 2016, 12, P960.	0.4	0



#	ARTICLE	IF	CITATIONS
271	P3-275: Increased TAU PET Signal Associated with Longitudinal Mr Atrophy in Cognitively Normal Older Adults. , 2016, 12, P940-P941.		0
272	P4-217: Regional Fluorodeoxyglucose Hypometabolism is Associated With Greater Apathy Over Time in Early Alzheimer's Disease. , 2016, 12, P1111-P1111.		0
273	ICâ€Pâ€053: Regional Fluorodeoxyglucose Hypometabolism is Associated with Greater Apathy Over Time in Early Alzheimer's Disease. Alzheimer's and Dementia, 2016, 12, P43.	0.4	0
274	P2-341: Subjective Cognitive Decline Predicts Longitudinal Decline in those with Both Amyloidosis and Neurodegeneration. , 2016, 12, P773-P774.		0
275	P3-322: Optimal Memory Performance in Older Adults is Associated with Differences in Hippocampal Volume and Amyloid Status at Baseline and Over 3 Years. , 2016, 12, P969-P969.		0
276	ICâ€Pâ€185: The Effect of Tractâ€Specific Loss of White Matter Connectivity on Cognitive Decline in Healthy Older Individuals Depends on Entorhinal T807 Binding. Alzheimer's and Dementia, 2016, 12, P135.	0.4	0
277	ICâ€Pâ€190: Increased TAU PET Signal Associated with Longitudinal Mr Atrophy in Cognitively Normal Older Adults. Alzheimer's and Dementia, 2016, 12, P137.	0.4	0
278	F1â€04â€01: Longitudinal Performance on the Preclinical Alzheimerâ€™s Cognitive Composite (PACC) in Subjects with Biomarkerâ€Defined Preclinical ad. Alzheimer's and Dementia, 2016, 12, P167.	0.4	0
279	O1â€13â€01: Anxiety, Social Activity and Amyloid in Cognitively Normal Older Adults. Alzheimer's and Dementia, 2016, 12, P208.	0.4	0
280	F3-04-01: In Vivo Cortical Distribution of Tau and Amyloid Deposits in Cognitively Normal Elderly. , 2016, 12, P274-P274.		0
281	O3â€08â€03: The Effect of Tractâ€Specific Loss of White Matter Connectivity on Cognitive Decline in Healthy Older Individuals Depends on Entorhinal T807 Binding. Alzheimer's and Dementia, 2016, 12, P304.	0.4	0
282	O3â€09â€03: Associations between Amyloidosis and Longitudinal Cognitive Decline in Clinically Normal Older Adults. Alzheimer's and Dementia, 2016, 12, P308.	0.4	0
283	O4â€01â€02: Tau and Amyloid Pet Imaging in a Colombian Kindred with Autosomalâ€Dominant Alzheimer's Disease. Alzheimer's and Dementia, 2016, 12, P330.	0.4	0
284	O4â€01â€06: Ab+ Clinically Normal Participants with Elevated Tau Show Greatest Decline in the Preclinical Alzheimerâ€™s Disease Cognitive Composite. Alzheimer's and Dementia, 2016, 12, P333.	0.4	0
285	O4-06-04: Neuroimaging Correlates of Anosognosia in Mild Cognitive Impairment. , 2016, 12, P345-P346.		0
286	O4â€07â€05: Pet Staging of Amyloidosis: Evidence that Amyloid Occurs First in Neocortex and Later in Striatum. Alzheimer's and Dementia, 2016, 12, P349.	0.4	0
287	P4-325: TAU BURDEN is Associated with Subjective Cognitive Concerns in the Context of Î²-Amyloid Burden in Preclinical ad. , 2016, 12, P1158-P1159.		0
288	ICâ€Pâ€198: TAU and Amyloid PET Imaging in a Colombian Kindred with Autosomalâ€Dominant Alzheimer's Disease. Alzheimer's and Dementia, 2016, 12, P143.	0.4	0

#	ARTICLE	IF	CITATIONS
289	[S2â€“01â€“01]: IMAGING AMYLOID AND TAU PATHOLOGY: LESSONS LEARNED. Alzheimer's and Dementia, 2017, 13, P541.	0.4	0
290	[O4â€“07â€“06]: <i>IN VIVO</i> SPREADING PATHWAYS OF TAU AND AMYLOID ACCUMULATION AND ITS GENETIC UNDERPINNINGS. Alzheimer's and Dementia, 2017, 13, P1246.	0.4	0
291	[P4â€“228]: LONGITUDINAL TAU ACCUMULATION IS ASSOCIATED WITH COGNITIVE DECLINE IN NORMAL ELDERLY. Alzheimer's and Dementia, 2017, 13, P1357.	0.4	0
292	[P4â€“243]: ANXIETY, SUBJECTIVE COGNITIVE DECLINE, AND CORTICAL AMYLOID IN PRECLINICAL AUTOSOMAL DOMINANT ALZHEIMER'S DISEASE: A PRELIMINARY REPORT. Alzheimer's and Dementia, 2017, 13, P1369.	0.4	0
293	[ICâ€“Pâ€“041]: SAMPLE SIZES FOR 24â€“MONTH ALZHEIMER'S PREVENTION TRIALS USING BIOMARKER ENDPOINTS IN COGNITIVELY UNIMPAIRED AMYLOIDâ€“POSITIVE ADULTS. Alzheimer's and Dementia, 2017, 13, P36.	0.4	0
294	[ICâ€“Pâ€“089]: ANXIETY, SUBJECTIVE COGNITIVE DECLINE, AND CORTICAL AMYLOID IN PRECLINICAL AUTOSOMAL DOMINANT ALZHEIMER'S DISEASE: A PRELIMINARY REPORT. Alzheimer's and Dementia, 2017, 13, P72.	0.4	0
295	[ICâ€“Pâ€“108]: ASSOCIATIONS BETWEEN MEASURES OF MEDIAL TEMPORAL LOBE NEURODEGENERATION AND ANOSOGNOSIA FOR MEMORY DEFICITS. Alzheimer's and Dementia, 2017, 13, P85.	0.4	0
296	[P1â€“256]: BASELINE CARDIOVASCULAR RISK AND AMYLOID BURDEN SYNERGISTICALLY PREDICT LONGITUDINAL COGNITIVE DECLINE IN CLINICALLY NORMAL ELDERLY: FINDINGS FROM THE HARVARD AGING BRAIN STUDY. Alzheimer's and Dementia, 2017, 13, P347.	0.4	0
297	[P1â€“398]: TAU ACCUMULATION IS DETECTABLE AND CORRELATED TO AMYLOID BURDEN IN NORMAL AND IMPAIRED OLDER INDIVIDUALS USING SERIAL PET. Alzheimer's and Dementia, 2017, 13, P423.	0.4	0
298	[P1â€“434]: RELATIONSHIPS BETWEEN MEMORY FUNCTION, TAU PATHOLOGY AND FUNCTIONAL CONNECTIVITY IN THE DEFAULT MODE NETWORK IN AUTOSOMALâ€“DOMINANT ALZHEIMER'S DISEASE: A PRELIMINARY REPORT. Alzheimer's and Dementia, 2017, 13, P448.	0.4	0
299	[P2â€“298]: ASSOCIATIONS BETWEEN MEASURES OF MEDIAL TEMPORAL LOBE NEURODEGENERATION AND ANOSOGNOSIA FOR MEMORY DEFICITS. Alzheimer's and Dementia, 2017, 13, P730.	0.4	0
300	[F1â€“03â€“02]: SUBJECTIVE COGNITIVE DECLINE, LONGITUDINAL COGNITIVE PERFORMANCE, AND IMAGING BIOMARKERS IN PRECLINICAL ALZHEIMER'S DISEASE. Alzheimer's and Dementia, 2017, 13, P176.	0.4	0
301	[O2â€“10â€“03]: SEVERITY OF SUBJECTIVE COGNITIVE DECLINE ALIGNS WITH REGIONAL AMYLOID SEVERITY: FINDINGS FROM THE HARVARD AGING BRAIN STUDY. Alzheimer's and Dementia, 2017, 13, P577.	0.4	0
302	[O2â€“11â€“04]: COGNITIVE RESERVE RELATES TO GREATER FUNCTIONAL CONNECTIVITY AND STRONGER INTERCONNECTIVITY WITHIN AND BETWEEN NODES, INDEPENDENT OF Î²â€“AMYLOID: FINDINGS FROM THE HARVARD AGING BRAIN STUDY. Alzheimer's and Dementia, 2017, 13, P582.	0.4	0
303	[O3â€“06â€“02]: SEMANTIC MEMORY AND PET AMYLOID AND TAU DEPOSITION IN PRECLINICAL AND PRODROMAL ALZHEIMER'S DISEASE. Alzheimer's and Dementia, 2017, 13, P911.	0.4	0
304	[O3â€“07â€“06]: THE RELATIONSHIP BETWEEN RECALL OF RECENTLY VERSUS REMOTELY ENCODED FAMOUS FACES AND AMYLOID AND TAU BURDEN IN CLINICALLY NORMAL OLDER ADULTS. Alzheimer's and Dementia, 2017, 13, P917.	0.4	0
305	[P1â€“030]: RELATIONSHIPS BETWEEN MEMORY FUNCTION, TAU PATHOLOGY AND FUNCTIONAL CONNECTIVITY IN THE DEFAULT MODE NETWORK IN AUTOSOMALâ€“DOMINANT ALZHEIMER'S DISEASE: A PRELIMINARY REPORT. Alzheimer's and Dementia, 2017, 13, P245.	0.4	0
306	O3â€“12â€“01: DECREASED METAâ€“MEMORY FOR EPISODIC BUT NOT SEMANTIC INFORMATION IS ASSOCIATED WITH EARLY TAUOPATHY IN CLINICALLY NORMAL OLDER ADULTS. Alzheimer's and Dementia, 2018, 14, P1050.	0.4	0

#	ARTICLE	IF	CITATIONS
307	P1â€³27: LONGITUDINAL DEPRESSIVE SYMPTOMS AND CORTICAL AMYLOID ARE ASSOCIATED WITH COGNITIVE DECLINE IN OLDER ADULTS. Alzheimer's and Dementia, 2018, 14, P417.	0.4	0
308	P3â€³090: JOINT DEBLURRING OF LONGITUDINAL DIFFERENTIAL PET IMAGES OF TAU. Alzheimer's and Dementia, 2018, 14, P1100.	0.4	0
309	P3â€³370: AN APOEÎ¼4 DERIVED STATISTICAL METHOD FOR OPTIMIZING TARGET AND REFERENCE REGIONS FOR AMYLOIDâ€³PET IMAGING. Alzheimer's and Dementia, 2018, 14, P1231.	0.4	0
310	P3â€³290: AMYLOID PATHOLOGY EXPLAINS UNAWARENESS OF MEMORY DEFICITS ABOVE AND BEYOND CORTICAL THICKNESS IN INDIVIDUALS WITH MILD COGNITIVE IMPAIRMENT. Alzheimer's and Dementia, 2018, 14, P1191.	0.4	0
311	O3â€³04â€³03: AMYLOID IS ASSOCIATED WITH GREATER TAU BURDEN IN CLINICALLY NORMAL FEMALES RELATIVE TO MALES: FINDINGS FROM TWO INDEPENDENT COHORTS. Alzheimer's and Dementia, 2018, 14, P1019.	0.4	0
312	O1â€³02â€³01: IMPACT OF DISCLOSING AMYLOID IMAGING RESULTS TO COGNITIVELY NORMAL RESEARCH PARTICIPANTS: THE A4 EXPERIENCE. Alzheimer's and Dementia, 2018, 14, P215.	0.4	0
313	P1â€³443: ASSOCIATION BETWEEN REGIONAL AMYLOID AND REGIONAL TAU IN YOUNGER, NONâ€³DEMENTED INDIVIDUALS IN THE FRAMINGHAM HEART STUDY. Alzheimer's and Dementia, 2018, 14, P482.	0.4	0
314	ICâ€³Pâ€³206: QUANTITATIVE SCORING OF [18F] FLORTAUCIPIR PET SCANS IN TYPICAL AND ATYPICAL PHENOTYPES OF ALZHEIMER'S DISEASE. Alzheimer's and Dementia, 2018, 14, P170.	0.4	0
315	ICâ€³Pâ€³159: BRAIN RESILIENCE PROTECTS AGAINST COGNITIVE DECLINE ASSOCIATED WITH ELEVATED AMYLOID BURDEN. Alzheimer's and Dementia, 2018, 14, P134.	0.4	0
316	F4â€³08â€³02: AMYLOID BURDEN AND VASCULAR RISK ARE INDEPENDENTLY ASSOCIATED WITH SUBJECTIVE COGNITIVE DECLINE IN CLINICALLY NORMAL OLDER ADULTS. Alzheimer's and Dementia, 2018, 14, P1394.	0.4	0
317	ICâ€³Pâ€³138: ASSOCIATION BETWEEN REGIONAL AMYLOID AND REGIONAL TAU WITHIN YOUNGER, NONâ€³DEMENTED INDIVIDUALS OF THE FRAMINGHAM HEART STUDY. Alzheimer's and Dementia, 2018, 14, P115.	0.4	0
318	P2â€³452: TAU ACCUMULATION IN RHINAL CORTEX IS ASSOCIATED WITH MEMORY PERFORMANCE IN NONDEMENTED YOUNG ADULTS WITH AUTOSOMAL DOMINANT ALZHEIMER'S DISEASE. Alzheimer's and Dementia, 2018, 14, P892.	0.4	0
319	O1â€³02â€³05: PREDICTING AMYLOID BURDEN IN SCREENING FOR PRECLINICAL AD PREVENTION TRIALS. Alzheimer's and Dementia, 2018, 14, P217.	0.4	0
320	O1â€³10â€³03: SEX AND <i>APOE</i> GENOTYPE INFLUENCE THE ASSOCIATION BETWEEN AMYLOID AND LONGITUDINAL TAU PATHOLOGY IN CLINICALLY NORMAL OLDER ADULTS: FINDINGS FROM THE ADNI STUDY. Alzheimer's and Dementia, 2018, 14, P243.	0.4	0
321	ICâ€³Pâ€³215: TAU ACCUMULATION IN RHINAL CORTEX IS ASSOCIATED WITH MEMORY PERFORMANCE IN NONâ€³DEMENTED YOUNG ADULTS WITH AUTOSOMAL DOMINANT ALZHEIMER'S DISEASE. Alzheimer's and Dementia, 2018, 14, P176.	0.4	0
322	ICâ€³Pâ€³139: LONGITUDINAL DEPRESSIVE SYMPTOMS AND CORTICAL AMYLOID ARE ASSOCIATED WITH COGNITIVE DECLINE IN OLDER ADULTS. Alzheimer's and Dementia, 2018, 14, P116.	0.4	0
323	P4â€³118: AV1451 TAU PET, BUT NOT CSF TAU, IS RELATED TO MEMORY DECLINE IN PRECLINICAL AND PRODROMAL ALZHEIMER'S DISEASE. Alzheimer's and Dementia, 2018, 14, P1484.	0.4	0
324	P1â€³301: CERTAIN PLASMA Nâ€³TERMINAL TAU FRAGMENTS ARE ELEVATED IN AD AND ADâ€³MCI COMPARED TO CONTROLS. Alzheimer's and Dementia, 2018, 14, P405.	0.4	0

#	ARTICLE	IF	CITATIONS
325	ICâ€Pâ€140: TAU ACCUMULATION AND MEMORY DECLINE ARE MORE CLOSELY RELATED TO STRIATAL THAN CORTICAL AMYLOIDOSIS IN INDIVIDUALS WITH EARLYâ€ONSET AUTOSOMAL DOMINANT ALZHEIMER'S DISEASE. Alzheimer's and Dementia, 2018, 14, P117.	0.4	0
326	P2â€461: ENTORHINAL TAU PATHOLOGY IS ASSOCIATED WITH WHITE MATTER ABNORMALITIES IN UNCINATE FASCICULUS IN PRECLINICAL AUTOSOMAL DOMINANT ALZHEIMER'S DISEASE. Alzheimer's and Dementia, 2018, 14, P897.	0.4	0
327	ICâ€Pâ€203: JOINT DEBLURRING OF LONGITUDINAL DIFFERENTIAL PET IMAGES OF TAU. Alzheimer's and Dementia, 2018, 14, P167.	0.4	0
328	O2â€08â€06: AMYLOIDâ€P, COGNITION AND SOCIAL ACTIVITY IN COGNITIVELY NORMAL OLDER ADULTS. Alzheimer's and Dementia, 2018, 14, P640.	0.4	0
329	0300 Linking Sleep Disturbances with Amyloid and Tau Imaging. Preliminary Findings from the Harvard Aging Brain Study. Sleep, 2019, 42, A122-A123.	0.6	0
330	ICâ€Pâ€178: SEX DIFFERENCES IN TAU PATHOLOGY ACROSS CORTICAL AND SUBCORTICAL REGIONS OF INTEREST: FINDINGS ACROSS TWO COHORTS. Alzheimer's and Dementia, 2019, 15, P139.	0.4	0
331	P4â€607: FREE AND CUED MEMORY IS DISTINCTLY RELATED TO PATHOLOGY IN PRECLINICAL AUTOSOMALâ€DOMINANT ALZHEIMER'S DISEASE. Alzheimer's and Dementia, 2019, 15, P1557.	0.4	0
332	ICâ€Pâ€037: GERIATRIC DEPRESSION SCALE ITEMâ€LEVEL ANALYSIS IN RELATION TOâ€IN VIVOâ€ CORTICAL AMYLOID AND CEREBRAL REGIONAL TAU IN CLINICALLY NORMAL OLDER ADULTS: FINDINGS FROM THE HARVARD AGING BRAIN STUDY. Alzheimer's and Dementia, 2019, 15, P43.	0.4	0
333	ICâ€Pâ€089: ASSOCIATIONS OF REGIONAL CORTICAL THINNING AND LONGITUDINAL COGNITIVE PERFORMANCE IN THE CONTEXT OF AMYLOID IN CLINICALLY NORMAL OLDER ADULTS. Alzheimer's and Dementia, 2019, 15, P79.	0.4	0
334	F2â€03â€01: CLINICAL MEANINGFULNESS OF SHORTâ€TERM COGNITIVE DECLINE ON THE PRECLINICAL ALZHEIMER'S COGNITIVE COMPOSITEâ€5 (PACCâ€5) IN NORMAL OLDER ADULTS WITH ELEVATED Î²â€AMYLOID. Alzheimer's and Dementia, 2019, 15, P518.	0.4	0
335	ICâ€Pâ€008: ANATOMICAL STAGING OF BETAâ€AMYLOID ACCUMULATION BASED ON LONGITUDINAL ASSESSMENT OF GLOBALLY PIB NEGATIVE ADULTS. Alzheimer's and Dementia, 2019, 15, P18.	0.4	0
336	ICâ€Pâ€067: TOPOGRAPHY OF CORTICAL THINNING IN THE LEWY BODY DEMENTIAS. Alzheimer's and Dementia, 2019, 15, P63.	0.4	0
337	P4â€608: TAU ACCUMULATION AND VISUAL MEMORY IN COGNITIVELY UNIMPAIRED PSEN1 E280A MUTATION CARRIERS. Alzheimer's and Dementia, 2019, 15, P1557.	0.4	0
338	ICâ€Pâ€058: COVARYING SPATIAL PATTERNS OF TAU DEPOSITION AND GRAY MATTER ATROPHY UNEARTHED BY THE INFORMED MULTIMODAL PARTIAL LEAST SQUARES (MMPLS) IN AUTOSOMAL DOMINANT ALZHEIMER'S DISEASE: FINDINGS FROM THE COLBOS PROJECT. Alzheimer's and Dementia, 2019, 15, P58.	0.4	0
339	O3â€09â€01: PROTECTIVE EFFECT OF PHYSICAL ACTIVITY ON LONGITUDINAL COGNITIVE DECLINE AND NEURODEGENERATION IN CLINICALLY NORMAL OLDER ADULTS WITH ELEVATED Î²â€AMYLOID BURDEN. Alzheimer's and Dementia, 2019, 15, P903.	0.4	0
340	Tracking the origin of tau spread in the brain. Alzheimer's and Dementia, 2020, 16, e037501.	0.4	0
341	Memory impairment is a clinical marker of tau pathology in cerebral amyloid angiopathy. Alzheimer's and Dementia, 2020, 16, e037524.	0.4	0
342	Alzheimerâ€™s disease biomarker roadmap 2020: [ 18 F]flortaucipir. Alzheimer's and Dementia, 2020, 16, e039550.	0.4	0

#	ARTICLE	IF	CITATIONS
343	Sex, tau, and cortical thinning in the temporal lobe: Findings from the Harvard Aging Brain Study. <i>Alzheimer's and Dementia</i> , 2020, 16, e040031.	0.4	0
344	The relationship between cortical microstructural changes and in vivo amyloid $\beta$ and tau in aging and preclinical Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2020, 16, e041626.	0.4	0
345	Longitudinal inferior temporal FTP $\beta$ PET signal increase is associated with contemporaneous longitudinal temporal lobe cortical thinning in preclinical Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2020, 16, e043419.	0.4	0
346	Estimating an individual's placement on a theoretical continuum using longitudinal cognitive trajectories: Relationships with longitudinal amyloid and Tau $\beta$ PET. <i>Alzheimer's and Dementia</i> , 2020, 16, e043566.	0.4	0
347	Associations of peak width of skeletonized mean diffusivity with cardiovascular disease risk and cognitive decline in clinically normal older adults. <i>Alzheimer's and Dementia</i> , 2020, 16, e043812.	0.4	0
348	Plasma IL $\beta$ 2/IFN $\beta$ axis predicts cognitive trajectories in cognitively normal older adults. <i>Alzheimer's and Dementia</i> , 2020, 16, e045497.	0.4	0
349	Distinct contributions of longitudinal tau and amyloid to decline in various cognitive domains in preclinical AD. <i>Alzheimer's and Dementia</i> , 2020, 16, e046075.	0.4	0
350	P3 $\beta$ 99: ASSOCIATION BETWEEN CORTICAL THINNING AND TAU PATHOLOGY IN PRECLINICAL AUTOSOMAL DOMINANT ALZHEIMER'S DISEASE. <i>Alzheimer's and Dementia</i> , 2018, 14, P1253.	0.4	0
351	Brainstem volume is negatively associated with amyloid deposition in the Framingham Heart Study. <i>Alzheimer's and Dementia</i> , 2021, 17, .	0.4	0
352	Cortical microstructure is associated with tau burden and predicts cognitive decline and clinical progression in healthy older adults. <i>Alzheimer's and Dementia</i> , 2021, 17, .	0.4	0
353	Associations between biomarker status (amyloid, tau) and risk for progression to MCI/Dementia in the Harvard Aging Brain Study. <i>Alzheimer's and Dementia</i> , 2021, 17, .	0.4	0
354	Locus coeruleus integrity as a proxy of initial tau burden: in vivo versus ex vivo observations. <i>Alzheimer's and Dementia</i> , 2021, 17, .	0.4	0
355	$^{18}\text{F}$ -flortaucipir PET imaging compared with autopsy in a clinically and pathologically heterogeneous group of patients with neurodegenerative dementias. <i>Alzheimer's and Dementia</i> , 2021, 17, .	0.4	0
356	Sequential early cognitive changes sensitive to rising beta $\beta$ amyloid and tau pathology in preclinical AD. <i>Alzheimer's and Dementia</i> , 2021, 17, .	0.4	0
357	Longitudinal associations between amyloid and tau $\beta$ PET: Impact for prevention trials. <i>Alzheimer's and Dementia</i> , 2021, 17, .	0.4	0
358	Associations between plasma p $\beta$ tau217, in vivo brain pathology and cognition in individuals with autosomal $\beta$ dominant Alzheimer's disease: Findings from the Columbia $\beta$ Boston (COLBOS) biomarker study. <i>Alzheimer's and Dementia</i> , 2021, 17, .	0.4	0
359	Self $\beta$ reported history of estrogen hormone therapy differentiates rates of amyloid accumulation (PiB $\beta$ PET) relative to males: Findings from the Harvard Aging Brain Study. <i>Alzheimer's and Dementia</i> , 2021, 17, .	0.4	0
360	Amygdala tau pathology in preclinical autosomal dominant Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2021, 17, .	0.4	0

#	ARTICLE	IF	CITATIONS
361	The combined influence of beta-amyloid and vascular risk on prospective brain atrophy in clinically normal individuals. <i>Alzheimer's and Dementia</i> , 2021, 17, .	0.4	0
362	Longitudinal trajectories of remote assessment of self- and study partner-rated cognitive concerns, mood and Alzheimer's disease biomarkers. <i>Alzheimer's and Dementia</i> , 2021, 17, .	0.4	0
363	Monthly computerized at-home assessments to detect cognitive change in preclinical Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2021, 17, .	0.4	0
364	Regional beta-amyloid and tau deposition: Results from the Framingham Heart Study. <i>Alzheimer's and Dementia</i> , 2021, 17, .	0.4	0
365	Association between the Harvard automated phone task and Alzheimer's disease pathology in clinically normal older adults. <i>Alzheimer's and Dementia</i> , 2021, 17, .	0.4	0
366	Multimodal neuroimaging biomarkers of Alzheimer's disease in older adults with depression: Preliminary findings from a pilot cohort. <i>Alzheimer's and Dementia</i> , 2021, 17, .	0.4	0
367	The location of <i>PSEN1</i> pathogenic variants in transmembrane vs. cytoplasmic domains may alter neurodegenerative and cognitive trajectories: Findings from the DIAN study. <i>Alzheimer's and Dementia</i> , 2021, 17, .	0.4	0
368	Associations Between Brainstem Volume and Alzheimer's Disease Pathology in Middle-Aged Individuals of the Framingham Heart Study. <i>Journal of Alzheimer's Disease</i> , 2022, 86, 1603-1609.	1.2	0
369	Locus coeruleus integrity predicts tau accumulation and memory dysfunction in autosomal dominant Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2021, 17 Suppl 3, e052664.	0.4	0
370	Heterogeneity of tau deposition and microvascular involvement in MCI and AD. <i>Alzheimer's and Dementia</i> , 2021, 17 Suppl 3, e054282.	0.4	0